Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

David R. Gandara(University of California, Davis), Sarah Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher(Kaiser Permanente Vallejo Medical Center), Geoff Otto(Foundation Medicine (United States)), Christine M. Malboeuf(Foundation Medicine (United States)), Daniel S. Lieber(Foundation Medicine (United States)), Doron Lipson(Foundation Medicine (United States)), Jacob Silterra(Foundation Medicine (United States)), Lukas C. Amler, Todd Riehl, Craig Cummings, Priti S. Hegde, Alan Sandler, Marcus Ballinger, David Fabrizio(Foundation Medicine (United States)), Tony Mok(Chinese University of Hong Kong), David S. Shames
Nature Medicine
July 30, 2018
Cited by 1,191

Abstract


Related Papers

No related papers found

Powered by citation graph analysis